Advanced NSCLC Monotherapy Treatment

Exploratory analysis:
PD-L1 expression levels ≥50%

In the subset of patients with advanced NSCLC* with no EGFR, ALK, or ROS1 aberrations and known PD-L1 ≥50% (n=563):

Exploratory analysis of PD-L1 expression1

Change in target tumor measurement with baseline PD-L1 tumor proportion scores1

Limitations:

This is an exploratory analysis that was not powered to show a statistically significant difference among or within varying PD-L1 expression levels. Firm conclusions cannot be made based on these exploratory analyses.

Exploratory analysis of tumor response by PD-L1 expression
  • Adapted with permission from Sezer et al, Lancet 2021.1
  • *Patients with locally advanced NSCLC who were not candidates for surgical resection or definitive chemoradiation or who had metastatic NSCLC.1
  • LOCF=last observation carried forward.

In the subset of patients with advanced NSCLC* with no EGFR, ALK, or ROS1 aberrations and known PD-L1 ≥50% (n=563):

Exploratory analysis of PD-L1 expression1

Overall survival and objective response with measurement with baseline PD-L1 tumor proportion scores1

Limitations:

This is an exploratory analysis that was not powered to show a statistically significant difference between or within varying PD-L1 expression levels. Firm conclusions cannot be made based on these exploratory analyses.

PD-L1 ≥90%
LIBTAYO (n=98)
Chemotherapy (n=94)
Overall survival
Median, months (95% CI)
NR (17.3-NE)
15.1 (11.1-NE)
Hazard ratio (95% CI)
0.46 (0.25-0.85)
Progression-free survival per BICR
Median, months (95% CI)
15.3 (10.4-18.7)
5.9 (4.3-6.2)
Hazard ratio (95% CI)
0.28 (0.17-0.46)
Tumor response per BICR
Objective response rate, % (95% CI)
46 (36-56)
18 (11-27)
 
LIBTAYO (n=89)
Chemotherapy (n=90)
Overall survival per BICR
Median, months (95% CI)
22.1 (17.9-NE)
12.0 (9.6-19.2)
Hazard ratio (95% CI)
0.47 (0.27-0.80)
Progression-free survival per BICR
Median, months (95% CI)
6.2 (4.2-8.4)
4.2 (4.1-5.7)
Hazard ratio (95% CI)
0.55 (0.38-0.80)
Tumor response per BICR
Objective response rate, % (95% CI)
39 (29-50)
20 (12-30)
 
LIBTAYO (n=96)
Chemotherapy (n=96)
Overall survival per BICR
Median, months (95% CI)
21.9 (13.2-NE)
14.0 (9.4-19.3)
Hazard ratio (95% CI)
0.77 (0.49-1.23)
Progression-free survival per BICR
Median, months (95% CI)
4.3 (2.8-6.3)
6.2 (5.0-6.2)
Hazard ratio (95% CI)
0.79 (0.56-1.12)
Tumor response per BICR
Objective response rate, % (95% CI)
32 (23-43)
23 (15-33)
 
  • Adapted with permission from Sezer et al, Lancet 2021.1
  • *Patients with locally advanced NSCLC who were not candidates for surgical resection or definitive chemoradiation or who had metastatic NSCLC.1
  • NR=not reached.